Posted by Michael Wonder on 11 Nov 2021
Patient access to affordable cancer treatment increases with the launch of new biosimilar in Canada
9 November 2021 - Apobiologix today launched its first oncology therapeutic treatment Bambevi (bevacizumab), which is used in combination with chemotherapy to treat specific types of colorectal, lung, brain and ovarian cancer.
Apobiologix's strategic partnership with Spanish-based biotechnology company mAbxience, supports the company's mission to transform access to affordable therapies in oncology and beyond.
